From: Triptans in prevention of menstrual migraine: a systematic review with meta-analysis
 | Country | Patients (n) * | Triptan | Dose | Migraine subtype | Treatment duration | Day of treatment onset | Consecutive PMP |
---|---|---|---|---|---|---|---|---|
Silberstein (2004) [33] | USA | 506 | frovatriptan | 2.5 mg QD or BID | MAM** | 6 | −2 | 1 |
Brandes (2009) [7] | International | 410 | frovatriptan | 2.5 mg QD or BID | MM | 6 | −2 | 3 |
Newman (2001) [34] | USA | 206 | naratriptan | 1 mg or 2.5mg BID | MAM** | 5 | −2 | 4 |
Mannix (s1) (2007) [35] | USA | 287 | naratriptan | 1 mg BID | MRM** | 6 | −3 | 4 |
Mannix (s2) (2007) [35] | International | 346 | naratriptan | 1 mg BID | MRM** | 6 | −3 | 4 |
Tuchman (2008) [36] | USA | 244 | zolmitriptan | 2.5 mg BID or TID | MM** | 7 | −2 | 3 |